Multiple myeloma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 7, Issue 9, 2009, Pages 908-942

  Anderson, Kenneth C ^a   Alsina, Melissa ^b   Bensinger, William ^c   Biermann, J Sybil ^d   Chanan Khan, Asher ^e   Cohen, Adam D ^f   Devine, Steven ^g   Djulbegovic, Benjamin ^b   Gasparetto, Cristina ^h   Huff, Carol Ann ⁱ   Jagasia, Madan ^j   Medeiros, Bruno C ^k   Meredith, Ruby ^l   Raje, Noopur ^m   Schriber, Jeffrey ⁿ   Singhal, Seema ^o   Somlo, George ⁿ   Stockerl Goldstein, Keith ^p   Tricot, Guido ^q   Vose, Julie M ^r   Weber, Donna ^s   Yahalom, Joachim ^t   Yunus, Furhan ^u   more..

^a Dana Farber/Brigham and Women's Cancer Center   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h DUKE CANCER INSTITUTE   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j VANDERBILT INGRAM CANCER CENTER   (United States)

^k STANFORD CANCER INSTITUTE   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

ⁿ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^o NORTHWESTERN UNIVERSITY   (United States)

^p BARNES JEWISH HOSPITAL   (United States)

^q UNIVERSITY OF UTAH   (United States)

^r NEBRASKA MEDICAL CENTER   (United States)

^s UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^t MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^u UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

more..

Author keywords

Bisphosphonates; C reactive protein; Combination chemotherapy; Cytogenetics; Immunomodulatory drugs; Multiple myeloma; NCCN Clinical Practice Guidelines; Novel therapies; Primary amyloidosis; Proteasome inhibitor; Stem cell transplant; Supportive therapies; Waldenstr m's monoclonal protein

Indexed keywords

ACICLOVIR; ALKYLATING AGENT; ANTIFUNGAL AGENT; BENDAMUSTINE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CALCITONIN; CALCIUM; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FLUDARABINE; FUROSEMIDE; HEMOGLOBIN; IMMUNOGLOBULIN; INTERFERON; LENALIDOMIDE; MELPHALAN; NUCLEOSIDE ANALOG; PNEUMOCOCCUS VACCINE; PREDNISONE; RITUXIMAB; STEROID; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

ALLOGENIC BONE MARROW TRANSPLANTATION; AMYLOIDOSIS; ANEMIA; ANTICOAGULANT THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; BRADYCARDIA; CALCIUM BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIAGNOSTIC APPROACH ROUTE; DRUG ERUPTION; DRUG MEGADOSE; HEMOGLOBIN BLOOD LEVEL; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERCALCEMIA; HYPERVISCOSITY SYNDROME; INFLUENZA VACCINATION; KIDNEY FAILURE; LIGHT CHAIN; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT ASSESSMENT; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PLASMACYTOMA; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; RECURRENT INFECTION; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; WALDENSTROEM MACROGLOBULINEMIA; ARTICLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA;

EID: 72149104327     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2009.0061     Document Type: Review

References (131)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Brenner H, Gondos A, Pulte, D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-2526.
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-2520.
4. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-937. (Pubitemid 37328894)
5. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
6. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a Workshop Report. Cancer Res 2004;64:1546-1558. (Pubitemid 38235629)
7. Dewald GW, Therneau T, Larson D, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005;106:3553-3558. (Pubitemid 41609193)
8. Moulopoulos LA, Dimopoulos MA, Weber D, et al. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 1993;11:1311-1315. (Pubitemid 23199135)
9. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:1457-1463.
10. Schirrmeister H, Bommer M, Buck AK, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:361-366. (Pubitemid 34253248)
11. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-224.
12. Tate JR, Gill D, Cobcroft R, Hickman PE. Practical considerations for the measurement of free light chains in serum. Clin Chem 2003;49:1252-1257. (Pubitemid 36900609)
13. Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:489-491.
14. Greipp P, Lust J, O'Fallon M, et al. Plasma cell labeling index and B2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993;81:3382-3387. (Pubitemid 23172924)
15. Greipp P, San Miquel J, Durie B, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420. (Pubitemid 46243484)
16. Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol 1983;1:255-262.
17. Dimopoulos MA, Goldstein J, Fuller L, et al. Curability of solitary bone plasmacytoma. J Clin Oncol 1992;10:587-590.
18. Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. Oncology 2000;14:101-111.
19. Kato T, Tsukamoto E, Nishioka T, et al. Early detection of bone marrow involvement in extramedullary plasmacytoma by whole-body F-18 FDG positron emission tomography. Clin Nucl Med 2000;25:870-873. (Pubitemid 30800884)
20. Schirrmeister H, Bommer M, Buck AK, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:361-366.
21. Jadvar H, Conti PS. Diagnostic utility of FEXJ PET in multiple myeloma. Skeletal Radiol 2002;31:690-694. (Pubitemid 36104567)
22. Orchard K, Barrington S, Buscombe J, et al. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol 2002;117:133-135. (Pubitemid 34304432)
23. Schirrmeister H, Buck AK, Bergmann L, et al. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm 2003;8:841-845. (Pubitemid 37377319)
24. Bredella MA, Steinbach L, Caputo G, et al. Value of FDG PET in the assessment of patients with multiple myeloma. Am J Roentgenol 2005;184:1199-1204. (Pubitemid 43821897)
25. Harousseau JL, Mathiot C, Attal M, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial [abstract]. J Clin Oncol 2008;26(Suppl 15):Abstract 8505.
26. Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycin, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM) (abstract). Blood 2008;112:243a. Abstract 653.
27. Cavo M, Tacchetti P, Patriarca F, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front Velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood 2008;112:Abstract 158.
28. Richardson P, Jagannath S, Raje N, et al. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase II study [abstract]. Blood 2007;110:Abstract 187.
29. Richardson P, Lonial S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study [abstract]. Blood 2008;112:Abstract 92.
30. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498. (Pubitemid 41007864)
31. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 trial. Blood 2006;108:2165-2172.
32. Zonder AJ, Crowley J, Hussein M, et al. Superiority of lenalidomide (Len) plus high-dose Dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232 [abstract]. Blood 2007;110:Abstract 77.
33. Rajkumar SV, Jacobus S, Callander N, et al. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood 2006;108:Abstract 799.
34. Rajkumar SV, Jacobus S, Callander N, et al. Randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood 2007;110:Abstract 74.
35. Paripati H, Stewart AK, Cabou S, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008;22:1282-1284. (Pubitemid 351833805)
36. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007;21:2035-2042. (Pubitemid 47299979)
37. Mazumder A, Kaufman J, Niesvizky R, et al. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008;22:1280-1281. (Pubitemid 351833803)
38. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-423.
39. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436. (Pubitemid 46630462)
40. Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer 2006;106:848-858.
41. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy vs. melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-342.
42. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-831. (Pubitemid 43363369)
43. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-1218. (Pubitemid 47516593)
44. Hulin C, Facon T, Rodon P, et al. Melphalan- prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01 [abstract]. Blood 2007;110:Abstract 75
45. Waage A, Gimsing P, Juliusson G, et al. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase III trial [abstract]. Blood 2007;110: Abstract 78.
46. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112:3107-3114.
47. Wijermans P, Schaafsma M, van Norden Y, et al. Melphalan + prednisone versus melphalan + prednisone + thalidomide induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch cooperative group HOVON [abstract]. Haematologica 2008;93:Abstract 178.
48. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
49. Miguel JFS, Schlag R, Khuageva NK, et al. Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma [abstract]. Blood 2008;112:Abstract 650.
50. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574-2579.
51. Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100:755-760. (Pubitemid 34832597)
52. Maloney D, Sahebi F, Stockerl-Goldstein KE, et al. Combining an allogenic graft versus myeloma effect with high dose autologous stem cell rescue in the treatment of multiple myeloma [abstract]. Blood 2001;98:Abstract 434a.
53. Moreau P, Facon T, Attal M, et al. Intergroupe Francophone du Myelome. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-735.
54. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97. (Pubitemid 26240110)
55. Child JA, Morgan GJ, Davies FE, et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
56. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high dose chemoradiotherapy for multiple myeloma. Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929-936.
57. Fermand JP, Katsahian S, Divine M, et al. High dose therapy and autologous blood stem cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227-9233.
58. Corradini P, Cavo M, Lokhorst H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma Blood 2003;102:1927-1929.
59. Kumar S, Lacy MQ, Dispenzieri A, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004;34:161-167. (Pubitemid 39077108)
60. Hahn T, Wingard JR, Anderson KC, et al. The role of cytotoxic therapy with haematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidenced based review. Biol Blood Marrow Transplant 2003;9:4-37. (Pubitemid 41123051)
61. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502. (Pubitemid 38010075)
62. Stadtmauer EA. Multiple myeloma 2004 - one or two transplants? N Engl J Med 2003;349:2551-2553.
63. Fermand JP, Katsahian S, Devine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227-9233.
64. Goldschmidt H. Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial [abstract]. Haematologica 2005;90(Suppl 1):Abstract 38.
65. Sonneveld P, van der Holt B, Segeren C, et al. Intensive versus double intensive therapy in untreated multiple myeloma: updated analysis of the randomized phase III study HOVON 24 MM [abstract]. Blood 2004;104:Abstract 948.
66. Cavo M, Tosi P, Zamagni, E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 Clinical Study. J Clin Oncol 2007;25:2434-2441. (Pubitemid 46999214)
67. Kyle RA. High dose therapy in multiple myeloma and primary amyloidosis: an overview. Semin Oncol 1999;26:74-83. (Pubitemid 29100359)
68. Kumar A, Loughran T, Alsina M, et al. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 2003;4:293-304. (Pubitemid 36592497)
69. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110-1120. (Pubitemid 46425595)
70. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474-3480.
71. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autograft for the treatment of patients with multiple myeloma. Blood 2003;102:3447-3454. (Pubitemid 37314788)
72. Crawley C, Lalancette M, Szydlo R, et al. Outcome for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;105:4532-4539. (Pubitemid 40720805)
73. Zeiser R, Bertz H, Spyridonidis A, et al. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant 2004;34:923-928. (Pubitemid 39600107)
74. Browman GP, Bergsagel D, Sicheri D, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995;13:2354-2360.
75. Shustik C, Belch A, Robinson S, et al. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: a National Cancer Institute of Canada Clinidal Trials Group Study: MY.7 [abstract]. J Clin Oncol 2004;22(Suppl 14):Abstract 6510.
76. Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomized trials among 3948 patients. Ann Oncol 2000;11:1427-1436.
77. Brinker BT, Waller EK, Leong T, et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 2006;106:2171-2180. (Pubitemid 43673239)
78. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289-3294. (Pubitemid 44776865)
79. Spencer A, Prince M, Roberts AW, et al. First analysis of the Australian leukaemia and lymphoma group (ALLG) trial of thalidomide and alternate day prednisone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLGMM6) [abstract]. Blood 2006;108:Abstract 58.
80. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup trial S9321. J Clin Oncol 2006;24:929-936. (Pubitemid 46638847)
81. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic cell transplantation for multiple myeloma. N Eng J Med 2006;354:1021-1030. (Pubitemid 43357806)
82. Richardson P, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-3560. (Pubitemid 350159621)
83. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151-157. (Pubitemid 44921846)
84. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-3901.
85. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142. (Pubitemid 350146108)
86. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 2007;357:2123-2132.
87. Richardson P, Jagannath S, Hussein M, et al. A muticenter, single arm, open label study to evaluate the efficacy and safety of single agent lenalidomide in patients with relapsed and refractory multiple myeloma [abstract]. Blood 2005;106:Abstract 2550.
88. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000;75:897-901. (Pubitemid 30690161)
89. Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732-2739. (Pubitemid 46606319)
90. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
91. Waage A, Gimsing P, Juliusson G, et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematology 2004;125:149-155. (Pubitemid 38534965)
92. Mohty M, Attal M, Marit G, et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Society Francaise de Greffe de Moelle et Therapie Cellulairs (SFGM-TC). Bone Marrow Transplant 2005;35:165-169.
93. Knop S, Straka C, Haen M, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287-1288. (Pubitemid 41375295)
94. Richardson P, Jagannath S, Avigan DE, et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial [abstract]. Blood 2006;108:Abstract 405.
95. Anderson KC, Jagannath S, Jakubowiak A, et al. Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM) [abstract]. J Clin Oncol 2008;26(Suppl 15):Abstract 8545.
96. Ikhlaque N, Seshadri V, Kathula S, Baumann MA. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol 2006;81:420-422. (Pubitemid 43787928)
97. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005;80:1568-1574. (Pubitemid 41747058)
98. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-493. (Pubitemid 26067736)
99. Berenson JR, Lichtenstein A, Porter L, et al. Long-term Pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593-602. (Pubitemid 28135605)
100. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-567. (Pubitemid 32112871)
101. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998;16:1218-1225.
102. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-2472.
103. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620-623. (Pubitemid 44253605)
104. Lindsley H, Teller D, Noonan B, et al. Hyperviscosity syndrome in multiple myeloma. A reversible, concentration-dependent aggregation of the myeloma protein. Am J Med 1973;54:682-688.
105. Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-1699. (Pubitemid 20231526)
106. Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. Blood 1996;87:2675-2682 (Pubitemid 26102216)
107. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:4784-4790.
108. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses: current approaches to diagnosis and treatment. N Engl J Med 1997;337:898-909.
109. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
110. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant: a case control study. Blood 2004;103:3960-3963. (Pubitemid 38596319)
111. Gertz MA, Lacy MQ, Dispenzieri A. Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev 2004;18:17-37. (Pubitemid 38200499)
112. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-2938. (Pubitemid 38451663)
113. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-4282. (Pubitemid 34627192)
114. Dhodapkar MV, Hussein MA, Rasmussen E, et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004;104:3520-3526.
115. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activiry of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465-470. (Pubitemid 46105939)
116. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007;109:492-496. (Pubitemid 46105943)
117. Wechalekar AD, Lachmann HJ, Offer M, et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008;93:295-298.
118. Dimopoulos MA, Alexanian R. Waldenström's macroglobulinemia. Blood 1994;83:1452-1459.
119. Ghobrial IM, Gertz MA, Fonseca R. Waldenström macroglobulinaemia. Lancet Oncol 2003;4:679-685.
120. McIntyre OR. Laboratory investigation of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, et al., eds. Myeloma: Biology and Management. Oxford: Oxford University Press; 1998:217.
121. Dimopoulos MA, Kantarjian H, Estey E, et al. Treatment of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993;118:195-198.
122. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327-2333.
123. Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 2001;19:3596-3601.
124. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570-1575. (Pubitemid 46733084)
125. Gertz MA, Anagnostopoulos A, Anderson KC, et al. Treatment recommendations in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003;30:121-126.
126. Gertz MA. Waldenström's macroglobulinemia: a review of therapy. Leuk Lymphoma 2002;43:1517-1526.
127. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009;27:120-126.
128. Dimopoulos MA, Kantarjian H, Weber D, et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994;2:2694-2698.
129. Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999;17:546-553.
130. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues. Leuk Lymphoma 1993;11(Suppl 2):105-108.
131. Treon SP, Agus DB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström's macroglobulinemia. J Immunotherapy 2001;24:272-279.